Literature DB >> 29189327

The Pancreatic Cancer Microenvironment.

Stephanie K Dougan1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is composed of a minority of malignant cells within a microenvironment of extracellular matrix, fibroblasts, endothelial cells, and immune cells. Therapeutic failures of chemotherapy, targeted therapy, and immunotherapy have all been attributed to the PDAC microenvironment. In this review, we dissect the components of the microenvironment and explain how each cell type contributes to form a highly immunosuppressive, hypoxic, and desmoplastic cancer. New efforts in single-cell profiling will enable a better understanding of the composition of the microenvironment in primary and metastatic PDAC, as well as an understanding of how the microenvironment may respond to novel therapeutic approaches.

Entities:  

Mesh:

Year:  2017        PMID: 29189327     DOI: 10.1097/PPO.0000000000000288

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  56 in total

1.  Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis.

Authors:  Zheng-Lin Ou; Zhen Luo; Wei Wei; Shuai Liang; Tai-Long Gao; Ye-Bin Lu
Journal:  RNA Biol       Date:  2019-08-12       Impact factor: 4.652

2.  FGD3 binds with HSF4 to suppress p65 expression and inhibit pancreatic cancer progression.

Authors:  Feng Guo; Xiang Cheng; Boping Jing; Heshui Wu; Xin Jin
Journal:  Oncogene       Date:  2022-01-03       Impact factor: 9.867

Review 3.  Carcinogenesis of Pancreatic Ductal Adenocarcinoma.

Authors:  Peter Storz; Howard C Crawford
Journal:  Gastroenterology       Date:  2020-03-19       Impact factor: 22.682

4.  Seven-gene signature on tumor microenvironment for predicting the prognosis of patients with pancreatic cancer.

Authors:  Bin Yang; Jinghua Xie; Zhiguo Li; Dan Su; Longfa Lin; Xiaofeng Guo; Zhiqiang Fu; Quanbo Zhou; Yanan Lu
Journal:  Gland Surg       Date:  2021-04

5.  A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses.

Authors:  Stanley L Liauw; Lisa Ni; Tianming Wu; Fauzia Arif; Denise Cloutier; Mitchell C Posner; Mark Kozloff; Hedy L Kindler
Journal:  J Gastrointest Oncol       Date:  2020-12

Review 6.  The biology of pancreatic cancer morphology.

Authors:  Oliver G McDonald
Journal:  Pathology       Date:  2021-12-03       Impact factor: 5.306

7.  Biomimetic stiffening of cell-laden hydrogels via sequential thiol-ene and hydrazone click reactions.

Authors:  Chun-Yi Chang; Hunter C Johnson; Olivia Babb; Melissa L Fishel; Chien-Chi Lin
Journal:  Acta Biomater       Date:  2021-06-01       Impact factor: 10.633

8.  A Space-Time Conversion Vehicle for Programmed Multi-Drugs Delivery into Pancreatic Tumor to Overcome Matrix and Reflux Barriers.

Authors:  Taotao Huo; Xiaoyi Zhang; Min Qian; Huifang Nie; Dong Liang; Chenteng Lin; Yafeng Yang; Wei Guo; Ulrich Lächelt; Rongqin Huang
Journal:  Adv Sci (Weinh)       Date:  2022-05-04       Impact factor: 17.521

9.  Glycolysis-Related Gene Expression Profiling Screen for Prognostic Risk Signature of Pancreatic Ductal Adenocarcinoma.

Authors:  Wenjing Song; Xin He; Pengju Gong; Yan Yang; Sirui Huang; Yifan Zeng; Lei Wei; Jingwei Zhang
Journal:  Front Genet       Date:  2021-06-23       Impact factor: 4.599

10.  Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.

Authors:  Rami Alzhrani; Hashem O Alsaab; Kushal Vanamal; Ketki Bhise; Katyayani Tatiparti; Ayatakshi Barari; Samaresh Sau; Arun K Iyer
Journal:  Adv Ther (Weinh)       Date:  2021-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.